Research Article
Portal Vein Stenting Combined with 125I Particle Chain Implantation Followed by As2O3 in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumour Thrombus
Table 3
Adverse events related to procedure.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note: data are number of patients (%); RILD = radiation-induced liver disease. Adverse events were assessed after 1 week of procedure. |